Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid Tumors
Status:
Terminated
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this multi-center, open-label, escalating dose study is to assess the safety
and tolerability of PPI-2458 in subjects with Non-Hodgkin's Lymphoma (NHL)and solid tumors.
Subjects will be treated every other day (QOD) with PPI-2458 while being monitored closely
for adverse events.